Total Funding
68
69
Total FundingVenture - Series Unknown raised
Growth Score
-15 pts
Heat Score
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
24808
Elevar Therapeutics specializes in clinical development of promising therapies for unmet medical needs in cancer.
- David Lilienfeld: VP of Drug Safety and Pharmacovigilance
- Wade Smith: Chief Financial Officer
About the Company
LSK BioPartners, Inc (dba LSK BioPharma) is a privately-held pharmaceutical company based in Salt Lake City, Utah with offices in South San Francisco (and Pangyo, South Korea). LSK BioPharma (LSKB) specializes in clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two proprietary drug candidates;
rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.
